L'intérêt à découvert pour TC BioPharm (Holdings) donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de TC BioPharm (Holdings). Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

TC BioPharm (Holdings) (NASDAQ:TCBP) Stock, Rapport sur les intérêts à découvert

TC BioPharm (Holdings)

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings) PLC

Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. The company reported quarterly sales of $794.900 million which missed the analyst consensus estimate of $800.580 million by 0.71 percent. This is a 2.19 percent increase over sales of $777.900 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Steelcase Q3 2025 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $794.900M Miss $800.580M Estimate

Third Quarter and Fiscal 2025 Outlook The table below presents our expectations for third quarter and selected full year fiscal 2025 financial operating results:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Q3 FY2025</td>
<td colspan="1" rowspan="1">Full Year FY25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">$903 million to $943 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross margin %</td>
<td colspan="1" rowspan="1">38.1% to 39.1%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating expenses&#x2A;</td>
<td colspan="1" rowspan="1">$293 million to $303 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest and other expense, net</td>
<td colspan="1" rowspan="1">$16.7 million to $17.7 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted effective tax rate&#x2A;</td>
<td colspan="1" rowspan="1">21.5% to 23.5%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted earnings per share - diluted&#x2A;</td>
<td colspan="1" rowspan="1">$0.41 to $0.47</td>
<td colspan="1" rowspan="1">$2.11 to $2.17</td>
</tr>
<tr>
<td colspan="3" rowspan="1">&#x2A;Items indicated represent Non-GAAP measures. The Q3 FY2025 outlook excludes an expected $6 million in operating expense charges related to amortization of Knoll purchased intangibles and the related tax and earnings per share impact.</td>
</tr>
</tbody>
</table>
</figure>
We are encouraged with both internal and external indicators that collectively support an expectation of improving demand trends in most of our markets.&nbsp; While we expect our fiscal third quarter to be impacted by typical seasonal softness in our Americas and International Contracts businesses as the calendar year comes to a close and by the timing of the Chinese New Year holiday, our full year guide reflects the improving demand trends. We narrowed our full year adjusted earnings per share range and modestly lowered the midpoint given the slower than expected macroeconomic improvements and lower than expected orders in the first half of the year. Our updated guidance continues to reflect full year sales and EPS growth over fiscal 2024.&nbsp;
Due to the timing dynamic of this year's holiday/cyber promotional period, we estimate approximately $12 million in Global Retail net sales shifted from our fiscal second quarter into our fiscal third quarter, as compared to the prior year.&nbsp; This is reflected in our third quarter guidance.

Guidance

MLKN

MillerKnoll Sees Q3 EPS $0.41-$0.47 Vs $0.56 Est.; Revenue $903M-$943M Vs $927.15M Est.

Biotech

General

IRIX

Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.

<h3>Gainers</h3>
<ul>
<li>Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) stock moved upwards by 16.1% to $44.37 during Wednesday's pre-market session. The company's market cap stands at $2.2 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) shares rose 12.65% to $1.78. The company's market cap stands at $22.4 million. </li>
<li>Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) shares moved upwards by 12.46% to $3.7. The company's market cap stands at $39.9 million. </li>
<li>Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) shares increased by 12.15% to $7.75. The market value of their outstanding shares is at $808.8 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock increased by 9.57% to $0.79. The market value of their outstanding shares is at $2.0 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock moved upwards by 9.57% to $1.6. The company's market cap stands at $14.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock decreased by 27.0% to $28.01 during Wednesday's pre-market session. The market value of their outstanding shares is at $563.1 million. </li>
<li>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) shares decreased by 9.45% to $1.62. The company's market cap stands at $8.5 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares fell 8.53% to $0.08. The company's market cap stands at $1.4 million. </li>
<li>Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares decreased by 7.62% to $12.86. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) stock declined by 7.6% to $2.31. The company's market cap stands at $2.6 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 5.61% to $1.18. The company's market cap stands at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CANG

EZGO

FTEL

HSAI

ISPO

JZXN

LXEH

RIME

VNCE

XWEL

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

SVRA

Savara Initiates Rolling Submission Of Biologics License Application To FDA For MOLBREEVI In Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis

Contracts

Parsons Announced It Has Been Awarded $20M U.S. Army Corps Of Engineers Contract For Puerto Rico Microgrid

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 148.4% to $1.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $46.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 140.95% to $2.53. The company's market cap stands at $10.6 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 68.18% to $0.79. The company's market cap stands at $6.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 44.02% to $0.09. The company's market cap stands at $13.2 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares increased by 22.79% to $0.41. The company's market cap stands at $76.6 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares rose 18.09% to $1.13. The company's market cap stands at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 34.8% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 33.5% to $4.2. The market value of their outstanding shares is at $2.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock fell 31.53% to $5.06. The market value of their outstanding shares is at $325.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares declined by 23.32% to $0.32. The market value of their outstanding shares is at $4.4 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 21.66% to $3.51. The company's market cap stands at $7.6 billion. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) stock fell 20.53% to $11.0. The company's market cap stands at $461.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

CGTX

CRVS

EVAX

NIVF

PLRZ

PTPI

RADX

RNAZ

SIBN

TCBP

TNXP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock moved upwards by 83.1% to $2.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $71.3 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) stock moved upwards by 32.81% to $0.3. The market value of their outstanding shares is at $4.8 million. </li>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) shares rose 21.91% to $1.5. The market value of their outstanding shares is at $142.1 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares moved upwards by 17.68% to $5.79. The market value of their outstanding shares is at $75.1 million. </li>
<li>Hyzon Motors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) shares rose 13.07% to $1.9. The company's market cap stands at $14.4 million. </li>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) stock increased by 12.58% to $0.72. The market value of their outstanding shares is at $16.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) stock declined by 16.6% to $3.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.4 million. </li>
<li>Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) stock decreased by 11.79% to $4.94. The market value of their outstanding shares is at $42.9 million. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) stock declined by 10.63% to $4.22. The market value of their outstanding shares is at $89.2 million. </li>
<li>Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) stock fell 9.49% to $77.22. The market value of their outstanding shares is at $8.0 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Mesa Air Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) shares decreased by 9.17% to $1.09. The market value of their outstanding shares is at $45.0 million. </li>
<li>ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) stock declined by 8.58% to $50.2. The market value of their outstanding shares is at $3.1 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EFSH

GWAV

HUHU

HYZN

MESA

SIDU

SYNX

VSTE

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 24.5% to $1.98 during Wednesday's pre-market session. The market value of their outstanding shares is at $35.9 million. </li>
<li>CommScope Hldg Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) stock moved upwards by 21.21% to $6.8. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock increased by 20.82% to $0.8. The market value of their outstanding shares is at $22.5 million. </li>
<li>Netgear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares increased by 18.57% to $30.45. The company's market cap stands at $885.2 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares increased by 15.36% to $19.37. The market value of their outstanding shares is at $2.3 billion. </li>
<li>WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) stock increased by 13.93% to $1.39. The market value of their outstanding shares is at $135.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock decreased by 12.8% to $3.08 during Wednesday's pre-market session. The company's market cap stands at $112.9 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares fell 11.35% to $1.25. The market value of their outstanding shares is at $37.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock declined by 9.0% to $0.91. </li>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) shares declined by 6.9% to $5.4. The market value of their outstanding shares is at $58.9 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) stock declined by 6.05% to $2.8. The company's market cap stands at $181.0 million. </li>
<li>IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) stock fell 5.89% to $41.26. The market value of their outstanding shares is at $8.8 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUID

CMBM

COMM

IONQ

LAES

LDTC

MAPS

NTGR

OPTX

QUBT

SOBR

VRAR

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.53 by 3.77 percent. This is a 6.78 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $970.40 million which beat the analyst consensus estimate of $959.70 million by 1.11 percent. This is a 2.20 percent increase over sales of $949.50 million the same period last year.

MillerKnoll Q2 Adj $0.55 Beats $0.53 Estimate, Sales $970.40M Beat $959.70M Estimate

A new analyst report that looks at downloads and user data could show the winners and losers and what's ahead for<a href="https://www.benzinga.com/topic/streaming"> the streaming sector.</a>
The Media and Internet Report: JPMorgan analysts led by David Karnovsky released a report on streaming downloads and user data using data from Sensor Tower, the iOS App Store and Google Play.
"Results in November were generally positive, with global downloads and DAUs mostly up on a sequential basis," the analyst report said.
Here's a look at some of the companies highlighted in the report.
The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): Disney+ downloads were down 6% month-over-month in November, which marked an improvement after two straight months of double-digit declines. The premiere of "Deadpool &amp; Wolverine" on the platform was the key release and may have led to some of the improved figures. The analyst said December includes the premieres of "Star Wars: Skeleton Crew," "Dream Productions" and "Doctor Who: Joy to the World." The ESPN tile being added to Disney+ could also help boost usage on the streaming platform, the analyst said, with some sports content available to Disney+ users without having a subscription.
"We think this is a positive step for the service and should boost overall engagement while potentially creating a new audience," the report noted.
Hulu, which is majority owned by Disney, saw downloads drop 5% month-over-month in November and daily active users fall 1% month-over-month, which came after two straight months of increases.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42537187/christmas-movie-with-the-rock-flops-at-box-office-breaks-streaming-records-for-this-company">Christmas Movie With The Rock Flops At Box Office, Breaks Streaming Records For This Company</a>
Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>): The media company is highlighted as a winner in the report with Paramount+ global downloads up 32% month-over-month in November, marking the platform's largest sequential gain since February 2024. The premiere of "Landman" and "The Agency" may have contributed to the gains. "Landman" was the biggest series launch on Paramount+ in two years according to the report.
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): Global downloads were up 14% year-over-year in November, an improvement from a -2% year-over-year decline in November. The increase may have been attributed by new content that included the Jake Paul vs. Mike Tyson live boxing event. The figures could get even better for the month of December.
"We believe content builds into year-end and 2025," the report said.
The report also cites several new movies and series along with the highly anticipated return of "Squid Game" and two NFL games on Christmas Day.
Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): Streaming platform Prime Video saw downloads down 7% year-over-year and daily active users down 8% year-over-year. The analysts expect a strong December for the platform with the premiere of "Beast Games" on Dec. 19 and several other series.
Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): Streaming platform Peacock saw November downloads up 31% month-over-month, which may have been thanks to 2024 election day coverage and the debut of "Twisters" during the month. A Black Friday special of $19.99 per year for Peacock may have also attributed to the better numbers, the analyst said.
Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>): Max downloads were up 20% month-over-month in November, with the launch of the streaming platform in Indonesia, Malaysia, Philippines, Singapore, Thailand, Taiwan and Hong Kong the likely reason. Downloads were down 5% month-over-month for the United States and Canada and up 29% in the other territories. Daily active users and monthly active users were also up month-over-month, including in the United States and Canada region.
Why It's Important: Based on the findings of the report, Paramount+ and Max are singled out as having strong Novembers. Prime Video and Netflix could be set for strong Decembers thanks to the release of "Beast Games" for Amazon and "Squid Game" and NFL games for Netflix.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/42199235/amazon-prime-vs-netflix-mrbeast-game-show-arrives-dec-19-squid-game-season-2-drops-1-week-later">Amazon Prime Vs. Netflix: MrBeast Game Show Arrives Dec. 19, &#8216;Squid Game&#8217; Season 2 Drops 1 Week Later</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Entertainment

Analyst Ratings

Trading Ideas

AMZN

CMCSA

NFLX

PARA

PARAA

Streamers Max, Paramount+ Won November: Here's Why Analyst Expects Netflix, Amazon To Win December

Offerings

QNCX

Quince Therapeutics Files For Mixed Shelf Offering Of Up To $200M

Management

ADSK

Autodesk Names John Cahill And Ram Krishnan To Join Board Effective Immediately; Lorrie Norrington Informs Her Intention Not To Stand For Re-election At 2025 Annual General Meeting

WIIM

Micron shares are trading lower following a Q1 revenue miss and weak Q2 guidance.

Micron Sees Q2 Revenue $7.7B-$8.1B vs $9.00B Est; Adj. EPS $1.33-$1.53 vs $1.92 Est

PLTR

Palantir Extends Long-standing Partnership With US Army To Deliver Army Vantage Capability In Support Of Army Data Platform; Total Value Of Agreement Is $400.74M For Period Of Up To Four Years, With Total Available Ceiling Of $618.87M

<ul>
<li>Breakthrough provides the first-ever certificates of authenticity and compliance for independent verification of AI training, inference, and benchmarks at runtime.</li>
<li>The solution delivers on-silicon, real-time governance — an industry-first created from two years of intensive research joined by advisors at Stanford and MIT.</li>
<li>Delivered this month to first clients with transformative applications across the life sciences, public sector, finance, and media to certify smarter, safer AI systems and agents.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eqtylab.io%2F&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=EQTY+Lab&amp;index=1&amp;md5=c10a00935d9dd60e9565ee82b154c342">EQTY Lab</a>, in collaboration with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.intel.com%2Fcontent%2Fwww%2Fus%2Fen%2Fhomepage.html&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=Intel&amp;index=2&amp;md5=f77b88357a53a6279a5450ba2839b0c5">Intel</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2F&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=NVIDIA&amp;index=3&amp;md5=ea11821b4ed59a27d1588b10ea5483af">NVIDIA</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), announced today the release of the Verifiable Compute AI framework, the first hardware-based solution to govern and audit AI workflows. Verifiable Compute represents a significant leap forward in ensuring that AI is explainable, accountable, and secure at runtime. It gives consumers and businesses new confidence to accelerate AI adoption and development.

INTC

NVDA

EQTY Lab, In Collaboration With Intel And NVIDIA Announces The Release Of The Verifiable Compute AI Framework, The First Hardware-Based Solution To Govern And Audit AI Workflows

Micron Technology Q1 2025 Adj. EPS $1.79 Beats $1.76 Estimate, Sales $8.709 Miss $8.721B Estimate

Throughout the last three months, 8 analysts have evaluated Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.38, with a high estimate of $64.00 and a low estimate of $37.00. Highlighting a 10.51% decrease, the current average has fallen from the previous average price target of $50.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1734555665_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Noble Corp among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Noble Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Noble Corp compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Noble Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Noble Corp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Noble Corp analyst ratings.</a>
<h2>Get to Know Noble Corp Better</h2>
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
<h3>Noble Corp: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Noble Corp displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.78%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Noble Corp's net margin excels beyond industry benchmarks, reaching 7.65%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Noble Corp's ROE stands out, surpassing industry averages. With an impressive ROE of 1.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Noble Corp's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: Noble Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Noble Corp Stock

Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $48.0, a high estimate of $52.00, and a low estimate of $41.00. This upward trend is evident, with the current average reflecting a 2.67% increase from the previous average price target of $46.75.
<img src="https://www.benzinga.com/files/images/story/2024/1734555657_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Brighthouse Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Brighthouse Finl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Brighthouse Finl compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Brighthouse Finl's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Brighthouse Finl's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BHF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Brighthouse Finl analyst ratings.</a>
<h2>About Brighthouse Finl</h2>
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, and Run-off. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
<h3>A Deep Dive into Brighthouse Finl's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Brighthouse Finl's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 75.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Brighthouse Finl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Brighthouse Finl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Brighthouse Finl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.06%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Brighthouse Finl's debt-to-equity ratio is below the industry average at 0.57, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Brighthouse Financial, Inc. - Common Stock

Brighthouse Finl Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

TC BioPharm (TCBP) announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treat...

TC Biopharm enters research pact with Dr. Carlos Maluquer de Motes

The company said, "TC BioPharm (TCBP) refuted a false claim made earlier this week on social media, stating there is absolutely no way the company ...

TC Biopharm refutes social media claim, remains compliant with Nasdaq rules

TC BioPharm (TCBP) announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex Grant Program. The G-ReX Grant Program, launc...

TC Biopharm awarded funding of $250,000 from G-Rex Grant Program

TC Biopharm (Holdings) Plc Sponsored ADR (TCBP) has released an update. TC Biopharm (Holdings) Plc has reported a challenging financial situation w...

TC Biopharm Faces Financial Strains Amid Rising Costs

16:08 EST TC Biopharm (TCBP) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaki...

TC Biopharm files $100M mixed securities shelf

TC BioPharm (TCBP) announced an update on the progression of the ACHIEVE UK Trial. As of this week, over half of the Cohort A patients in Stage One...

TC Biopharm provides quarterly update on ACHIEVE UK Trial

H.C. Wainwright lowered the firm's price target on TC Biopharm (TCBP) to $3 from $7 and keeps a Buy rating on the shares. The firm updated its mode...

TC Biopharm price target lowered to $3 from $7 at H.C. Wainwright

TC BioPharm (TCBP) announced a partnership with CareDx (CDNA) who will perform pharmacokinetic analysis using its AlloCellsolution in the ACHIEVE c...

TC Biopharm announces partnership with CareDx

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm (Holdings) plc has announced a General Meeting sche...

TC BioPharm Announces Key Shareholder Meeting

The latest announcement is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm (Holdings) Plc has filed a prospectus supplem...

TC BioPharm Advances Strategic Financial Initiative with New ADS Offering

CDNA

Press Releases

TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening

TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic

Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

Shares of This Biotech Surge Following Collaboration Announcement For Monkeypox Research

Social Media

TCBP Responds to False Social Media Claim

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

Dividends

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

CRDL

CYCC

GNPX

PRSO

TSX:CRDL

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

Anitra

Bionomics Limited - American Depository Shares

Bionomics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Carmell

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Oragenics

Onconetix

Palisade Bio

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Comments

TC BioPharm (Holdings)

Intérêt court

TC BioPharm (Holdings) (NASDAQ:TCBP) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL